Natriuretic Peptide Receptor A as a Novel Target for Prostate Cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Wang, Xiaoqin ^a   Raulji, Payal ^a   Mohapatra, Shyam S ^a,d   Patel, Ronil ^a   Hellermann, Gary ^a   Kong, Xiaoyuan ^a   Vera, Pedro L ^a,b   Meyer Siegler, Katherine L ^b   Coppola, Domenico ^c   Mohapatra, Subhra ^a,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Bay Pines Veterans Affairs Healthcare System   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR A INHIBITOR; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; ISOMERASE; MIF PROTEIN, HUMAN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE COURSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PROSTATE TUMOR; RABBIT; RAT; TUMOR VOLUME;

MUS;

ANIMALS; APOPTOSIS; CELL LINE; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; PROSTATIC NEOPLASMS; RABBITS; RATS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, SMALL INTERFERING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955954920     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-56     Document Type: Article

References (49)

1. Goggins WB, Wong GK. Poor survival for US Pacific Islander cancer patients evidence from the Surveillance, Epidemiology, and End Results database: 1991 to 2004. J Clin Oncol 2007, 25:5738-5741. 10.1200/JCO.2007.13.8271, 18089868.
2. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the US. Cancer Causes Control 2007,
3. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 2007, 25:398-400. 10.1016/j.urolonc.2007.05.007, 17826659.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269. 10.1038/nrc2090, 17384581.
5. Nelson WG. Prostate cancer prevention. Curr Opin Urol 2007, 17:157-167. 10.1097/MOU.0b013e3280eb110f, 17414513.
6. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001, 57:46-51. 10.1016/S0090-4295(00)00940-7, 11295594.
7. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
8. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000, 7:169-170.
9. Mohapatra SS, Lockey RF, Vesely DL, Gower WR. Natriuretic peptides and genesis of asthma: an emerging paradigm?. J Allergy Clin Immunol 2004, 114:520-526. 10.1016/j.jaci.2004.05.028, 15356551.
10. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli AA, Solivan SM, Gower WR, Vesely DL. Five cardiac hormones decrease the number of human small-cell lung cancer cells. Eur J Clin Invest 2005, 35:388-398. 10.1111/j.1365-2362.2005.01501.x, 15948900.
11. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153-159. 10.1080/15216540212336, 12102171.
12. Vesely DL, Perez-Lamboy GI, Schocken DD. Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. Life Sci 2000, 66:905-913. 10.1016/S0024-3205(99)00674-8, 10714891.
13. Kiemer AK, Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 2001, 60(Suppl 3):iii68-70. 1766678, 11890659.
14. Hellermann G, Kong X, Gunnarsdottir J, San Juan H, Singam R, Behera S, Zhang W, Lockey RF, Mohapatra SS. Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol 2004, 113:79-85. 10.1016/j.jaci.2003.10.009, 14713911.
15. Kumar M, Behera AK, Lockey RF, Vesely DL, Mohapatra SS. Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization. J Allergy Clin Immunol 2002, 110:879-882. 10.1067/mai.2002.129699, 12464954.
16. Mohapatra SS. Role of natriuretic peptide signaling in modulating asthma and inflammation. Can J Physiol Pharmacol 2007, 85:754-759. 10.1139/Y07-066, 17823639.
17. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells. Anticancer Res 2006, 26:3217-3222.
18. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007, 27:1387-1392.
19. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, Lockey RF, Mohapatra S, Mohapatra SS. Natriuretic peptide receptor a as a novel anticancer target. Cancer Res 2008, 68:249-256. 10.1158/0008-5472.CAN-07-3086, 18172317.
20. Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey RF, Mohapatra SS. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther 2008, 6:7. 10.1186/1479-0556-6-7, 2291050, 18279512.
21. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995, 378:65-68. 10.1038/378065a0, 7477288.
22. Gower WR, Carter GM, McAfee Q, Solivan SM. Identification, regulation and anti-proliferative role of the NPR-C receptor in gastric epithelial cells. Mol Cell Biochem 2006, 293:103-118. 10.1007/s11010-006-9234-3, 16786190.
23. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997, 57:3325-3330.
24. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007, 67:6083-6091. 10.1158/0008-5472.CAN-06-4202, 17616663.
25. Wang X, Xu W, Kong X, Chen D, Hellermann G, Ahlert TA, Giaimo JD, Cormier SA, Li X, Lockey RF, et al. Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma. Respir Res 2009, 10:66. 10.1186/1465-9921-10-66, 2716304, 19615076.
26. Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007, 12:1475-1487. 10.2741/2161, 17127395.
27. He Z, Ong CH, Halper J, Bateman A. Progranulin is a mediator of the wound response. Nat Med 2003, 9:225-229. 10.1038/nm816, 12524533.
28. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364.
29. Kawada M, Inoue H, Usami I, Takamoto K, Masuda T, Yamazaki Y, Ikeda D. Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance. Cancer Lett 2006, 242:46-52. 10.1016/j.canlet.2005.10.040, 16377078.
30. Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, Holland JF, Levine AC. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun 2002, 290:249-255. 10.1006/bbrc.2001.6188, 11779161.
31. Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, Leng L, Bucala R. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 2007, 8:646-652. 10.1038/sj.gene.6364427, 17728788.
32. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006, 177:8730-8739.
33. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005, 5:73. 10.1186/1471-2407-5-73, 1177932, 16000172.
34. Vesely BA, Alli AA, Song SJ, Gower WR, Sanchez-Ramos J, Vesely DL. Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 2005, 35:700-710. 10.1111/j.1365-2362.2005.01569.x, 16269020.
35. Bell EN, Tse MY, Frederiksen LJ, Gardhouse A, Pang SC, Graham CH, Siemens DR. Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells. J Urol 2007, 177:751-756. 10.1016/j.juro.2006.09.075, 17222675.
36. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006, 26:4143-4148.
37. Cao L, Wu J, Gardner DG. Atrial natriuretic peptide suppresses the transcription of its guanylyl cyclase-linked receptor. J Biol Chem 1995, 270:24891-24897. 10.1074/jbc.270.42.24891, 7559613.
38. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J, Mucci LA. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009, 124:2683-2689. 10.1002/ijc.24241, 2667697, 19189403.
39. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 2009, 26:10-15. 10.1007/s12032-008-9070-2, 18461289.
40. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007, 109:875-881. 10.1002/cncr.22461, 17265528.
41. Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, Calle EE. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2009, 20:671-679. 10.1007/s10552-008-9280-0, 19067188.
42. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001, 61:6777-6782.
43. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90:2312-2316. 2409519, 15150588.
44. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?. World J Urol 2007, 25:477-489. 10.1007/s00345-007-0175-6, 17541600.
45. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001, 12:33-40. 10.1016/S1359-6101(00)00021-6, 11312117.
46. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001, 48:47-53. 10.1002/pros.1080, 11391686.
47. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995, 55:4633-4639.
48. Hamatake M, Yoshino I, Tomiyasu M, Miura N, Okazaki H, Ohba T, Takenaka T, Maehara Y. Intratumoral expression of macrophage migration inhibitory factor is correlated with serum C-reactive protein and interleukin-6 in patients with non-small cell lung cancer. Surg Today 2008, 38:921-925. 10.1007/s00595-008-3765-z, 18820867.
49. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005, 65:7717-7723.